Khodjanova SHI, Alyavi AL
From the standpoint of evidence-based medicine, the prescription of antiplatelet drugs for the primary and secondary prevention of acute cardiovascular events is an essential component of the pharmacotherapy of ischemic heart disease (IHD). Currently, one of the most prescribed drugs for oral antiplatelet therapy for cardiovascular diseases, the "gold standard" is acetylsalicylic acid (ASA), which has the greatest evidence base among all antiplatelet drugs. However, recently there has been an increasing number of concerns where it has been shown that a third of patients develop resistance to aspirin, especially in patients who take it for a long time in low doses. A serious problem remains the relatively high frequency of recurring ischemic events in these patients, and they seem to have a worse prognosis than patients with clear ASA-dependent do inhibition of platelet function. This phenomenon, called aspirin resistance, dictates the need for a differentiated approach to the prevention and treatment of IHD. The article is about current problems of aspirin resistance to antithrombotic therapy in IHD.The question of the etiological factors andepidemiology of aspirin resistance is being considered. Various laboratory methods for evaluating this phenomenon are given.
Pages: 20-24 | 1295 Views 592 Downloads